|
|
Article: Neurocrine Reports Additional Positive Results From Phase III Chronic Insomnia Trial; Indiplon Shows No Evidence of Rebound Insomnia or Withdrawal.
- Article from:
- PR Newswire
- Article date:
- May 19, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced that indiplon shows no evidence of rebound insomnia or withdrawal in a Phase III clinical trial with two doses (10 mg and 20 mg) of the immediate release formulation of indiplon in 200 patients with Chronic Primary Insomnia. Along with previously reported efficacy and safety results, this study was designed to evaluate the potential for rebound insomnia and withdrawal effects after discontinuation of indiplon after 35 consecutive nights of treatment.
Rebound insomnia is an increase in the time it takes to fall asleep upon cessation of treatment as compared to the time to fall asleep prior to the initiation of ...